Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals

Azam, Faisal; Latif, Muhammad Farooq; Farooq, Ayesha; Tirmazy, Syed Hammad; Alshahrani, Saad; Bashir, Shahid; Bukhari, Nedal

doi:10.1159/000503095

Cited by 201 publications

(155 citation statements)

References 16 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…A review of the literature reflects the lack of unified general criteria and norms for assessing the quality of life in NHL patients. Regardless of the stage of the disease and the histological type of NHL, an impaired performance status is a major obstacle, which contraindicates chemotherapy or limits the application of specific treatment in the required volume, which negatively influences the patient's quality of life 9,22,23 .…”

Section: Discussionmentioning

confidence: 99%

“…The tools applied to the study of quality of life are profiles and questionnaires that allow the evaluation of each component of quality of life separately involving a specific assessment of a phenomenon 8 . Eastern Cooperative Oncology Group (ECOG) performance status is used by oncologists to assess patients' degree of independence in cytostatic therapy and to predict the prognosis in malignancies with a high degree of spread 9 . The European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire is one of the most widely used questionnaires in the last 30 years in researching the quality of life of patients with oncological diseases (2010 evaluation report of the QLG Scientific Committee) 10 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antioxidant density in plant foods typical in Bulgarian diet and healthy ageing

Tsanova-Savova¹,

Savova²,

Ribarova³

2020

Arch Balk Med Union

View full text Add to dashboard Cite

L'évaluation de la qualité de vie des patients atteints de lymphome NH est-elle un fardeau ou un avantage ? Introduction. Les lymphomes non Hodgkiniens (LNH) sont des néoplasies développées à partir des tissus lymphoides. Le traitement moderne du LNH permet de prolonger la durée de vie des patients,mais en même temps les complications somatiques et psychologiques présentent un risque de réduire la qualité de vie des patients. L'objectif de l'étude a été l'evaluation de la qualité de vie des patients atteints de LNH. Matériel et méthodes. Nous avons conduit une étude observationnelle incluant des patients diagnostiqués avec un LNH agressif et indolent. La qualité de vie a été calculée avec l'aide de l'instrument d'évaluation standard Eastern Cooperative Oncology Group (ECOG), Global Well-Being Group (GWB) et European Organization for the Resear ch and Treatment of Cancer (EORTC) QLQ-C30.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antioxidant density in plant foods typical in Bulgarian diet and healthy ageing

Tsanova-Savova¹,

Savova²,

Ribarova³

2020

Arch Balk Med Union

View full text Add to dashboard Cite

show abstract

“…Performance status was measured using the Eastern Cooperative Oncology Group score [ 19 ] as follows; Grade 0—fully active with no physical restrictions; Grade 1—some physical restriction but able to carry out light work; Grade 2—ambulatory and capable of self-care but unable to carry out any work activity. Confined to bed or wheelchair less than 50% of waking hours; Grade 3—capable of only limited self-care.…”

Section: Methodsmentioning

confidence: 99%

Gender Differences in Oesophageal Squamous Cell Carcinoma in a South African Tertiary Hospital

Ferndale

Aldous

Hift

et al. 2020

IJERPH

View full text Add to dashboard Cite

(1) Oesophageal squamous cell carcinoma is common in Africa and has a male preponderance. The gender-based differences in clinical presentation and risk factor exposure are poorly studied in the African context. Our aim was to compare males and females with this disease. We analyzed the differences in clinical features and risk factor exposure between males and females with oesophageal cancer. (2) Data from patients presenting to a tertiary hospital in South Africa with oesophageal squamous cell carcinoma were analyzed. Data collected included patient demographics, clinical presentation, pathology and risk factor exposure. (3) Three hundred and sixty three patients were included in the study. The male to female ratio was 1.4:1. The mean age was 66 years for females and 61 years for males (p < 0.0001). A significantly larger percentage of males were underweight compared to females (60% vs. 32%, p < 0.001). There were no differences between the genders with regards to performance status, dysphagia grade and duration and tumor length, location and degree of differentiation. There were significant differences between risk factor exposure between the two genders. Smoking and alcohol consumption was an association in more than 70% of males but in less than 10% of females There was no difference survival. (4) Female patients with oesophageal squamous cell carcinoma (OSCC) are older and have a higher body mass index (BMI) than their male counterparts. Traditionally purported risk factors of smoking and alcohol consumption are infrequent associations with OSCC in female patients and other environmental risk factors may be more relevant in this gender.

show abstract

“…A total of consecutive 39 patients (age, 47–75 years; 26 male patients and 13 female patients) with advanced NSCLC, who underwent apatinib plus docetaxel treatment or docetaxel alone treatment, were retrospectively enrolled in The First Affiliated Hospital of Nanjing Medical University between January 2017 and December 2018. The inclusion criteria were as follows: i) Diagnosed with primary NSCLC at stage IV or recurrent metastatic NSCLC refractory/intolerant to standard therapy; ii) age ≥18 years; iii) a baseline Eastern Cooperative Oncology Group performance status score of 0–1 ( 13 ); iv) adequate hematologic, hepatic and renal functions; v) cessation of other anti-tumor therapies for ≥1 month prior to enrollment; vi) presence of ≥1 measurable lesion defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) ( 14 ); and vii) a survival prognosis of >3 months. Furthermore, the exclusion criteria were as follows: i) Previously treated with immunotherapy; ii) untreated metastases of the central nervous system; iii) uncontrolled blood pressure with medication (>140/90 mmHg); iv) serious infection or autoimmune disease; v) bleeding tendency; and vi) hepatopathy, nephropathy, cardiopathy, respiratory disease or uncontrollable diabetes.…”

Section: Methodsmentioning

confidence: 99%

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

Hui

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

The prognosis of advanced non-small cell lung cancer (nSclc) is poor; therefore, identifying novel treatment strategies for patients with nSclc is important. The present study aimed to investigate the efficacy of apatinib plus docetaxel vs. docetaxel alone, as well as their effects on regulating autophagy markers in patients with advanced nSclc. Furthermore, it was evaluated whether apatinib sensitized chemoresistant nSclc cells to docetaxel via regulating autophagy. a total of 39 patients with advanced nSclc were consecutively enrolled and treated with apatinib plus docetaxel (n=19) or docetaxel alone (n=20) for four treatment cycles. The treatment response, adverse events and expression levels of autophagy markers [(light chain 3 α (lc3a) and Beclin-1] were evaluated in tumor samples, which were obtained via biopsy, before treatment and after 2-cycle treatment. In addition, in a mechanistic in vitro experiment, apatinib, docetaxel, the autophagy activator rapamycin and the autophagy inhibitor 3-methyladenine (3-Ma) were used to treat docetaxel-resistant A549 (A549/DTX) cells alone or in various combinations. The expression levels of LC3A, Beclin-1, poly (ADP) ribose polymerase (ParP) and phosphorylated (p)-aKT were detected via western blotting, while the cell apoptosis rate was detected with an annexin V/Pi assay. The overall remission rate (37 vs. 10%; P=0.047) and disease control rate (84 vs. 45%; P=0.011) were increased in the Apatinib plus docetaxel group compared with the docetaxel group. Most of the adverse events were mild and tolerable, and there was no difference between the two groups except for total hypertension and hand-foot syndrome, which were higher in the Apatinib plus docetaxel group). compared with the levels prior to treatment, Beclin-1 and lc3a remained unchanged post-treatment in the Apatinib plus docetaxel group, while they were increased in the docetaxel group. docetaxel increased lc3a, Beclin-1 and p-aKT expression levels, ParP cleavage and the cell apoptosis rate in a549/dTX cells, and rapamycin further enhanced, while 3-Ma reduced these effects of docetaxel. Moreover, apatinib repressed LC3A, Beclin-1, p-AKT expression levels and promoted the cell apoptosis rate in a549/dTX cells and docetaxel-treated a549/dTX cells. in conclusion, apatinib synergize the effect of docetaxel in treating patients with advanced nSclc and chemoresistant nSclc cells via inhibiting autophagy.

show abstract

Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals

Cited by 201 publications

References 16 publications

Antioxidant density in plant foods typical in Bulgarian diet and healthy ageing

Antioxidant density in plant foods typical in Bulgarian diet and healthy ageing

Gender Differences in Oesophageal Squamous Cell Carcinoma in a South African Tertiary Hospital

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

Contact Info

Product

Resources

About